ArticleThe Journal of organic chemistry2025
Oxygen-Independent Activatable Photosensitizers Based on the Control of Intersystem Crossing with a Tetrad-BODIPY Scaffold.
Article in The Journal of organic chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanism-guided design of specific-activated photosensitizers for precision photodynamic therapy.Chemical science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A compact photosensitizer platform has been developed to enable precise and tunable control over intersystem crossing (ISC) without the use of heavy atoms. The tetrad-based molecular architecture incorporates a simple electron-withdrawing substituent, allowing ISC to be switched OFF and the photosensitizer to remain inactive until reactivated. This design achieves an exceptionally long excited-state lifetime of 142 μs, facilitating low-dose operation with phototoxic efficacy that is virtually independent of oxygen concentration. The heavy-atom-free structure minimizes dark toxicity and enhances intracellular distribution. By overcoming key limitations of conventional photosensitizers─such as reliance on heavy atoms, poor selectivity, and lack of spatiotemporal control─the platform establishes a universal scaffold for biomedical applications. Beyond photodynamic therapy, the system provides a foundational molecular tool for optobiology, enabling light-mediated regulation of biological functions with high precision. These features position the photosensitizer as a versatile agent for advancing therapeutic strategies and light-regulated life sciences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.